Table 5– Most common on-treatment adverse events (≥3% incidence in any treatment group).
Placebo | Salmeterol | GSK961081 | ||||||
Twice daily | Once daily | |||||||
100 μg | 200 μg | 400 μg | 100 μg | 400 μg | 800 μg | |||
Subjects | 81 | 47 | 52 | 50 | 54 | 50 | 50 | 52 |
Any adverse event | 20 (25) | 8 (17) | 12 (23) | 12 (24) | 16 (30) | 16 (32) | 15 (30) | 13 (25) |
Headache | 5 (6) | 2 (4) | 2 (4) | 5 (9) | 5 (10) | 5 (10) | 2 (4) | |
Cough | 2 (2) | 2 (4) | 4 (8) | 1 (2) | 5 (10) | 5 (10) | 4 (8) | |
Dysgeusia | 2 (4) | 3 (6) | 3 (6) | 2 (4) | 1 (2) | |||
Nasopharyngitis | 3 (4) | 1 (2) | 3 (6) | 3 (6) | 1 (2) | |||
Back pain | 2 (2) | 1 (2) | 2 (4) | |||||
Dysphonia | 2 (2) | 1 (2) | 2 (4) | |||||
Muscle spasms | 1 (2) | 1 (2) | 2 (4) | 1 (2) | ||||
Nausea | 2 (2) | 1 (2) | 2 (4) | |||||
Myalgia | 1 (1) | 1 (2) | 2 (4) | |||||
Palpitations | 1 (2) | 2 (4) |
Data are presented as n or n (%).